Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
💊 Oral IL-23Ri for #PsA #PsO?
ICONIC RCT (n=216):
Yes! Icotrokinra improves pain & disease activity at week 16
#POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
🛡️ Can secukinumab prevent #PsA?
SERENA real-world study (n=1,334):
Yes!
97% PsA-free at 5yrs
#POS0051 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
💉 Add tirzepatide to biologics in obese #PsA?
#POS0050: Yes! Propensity score-matched study (n=93):
better PROs, HAQ & PASI at 6 months
#EULAR2026 @RheumNow
@vincevenerito https://t.co/rrhNKZByjc
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
🎯 Does Tofacitinib work in axial #PsA?
#POS0049: 1st RCT (PASTOR, n=26):
improved MRI & clinical outcomes vs placebo @ wk12
#EULAR2026 @rheumnow
Janet Pope Janetbirdope
3 months 3 weeks ago
You CAN identify #ILD in #rheumatic #diseases
🔜early
With a brief #questionnaire
Ask re
➡️dry cough
➡️dyspnea
➡️smoking
Not sensitive but high #specificity
Is it too late?
Maybe chest #auscultation at the #bases would be better?
🤷
#EULAR2026 ABST#POS0433
@RheumNow https://t.co/JA3k1cSHt7
Jiha Lee JihaRheum
3 months 3 weeks ago
Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) vs 16% worsening on placebo at wk 24, plus PASI 100 in ~39% vs 11%. IL-23 inhibition delivering where pts often struggle most. @RheumNow #EULAR2026 POS0471
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
BKZ protect joints in #PsA long-term?
#POS0048: Phase 3 RCT+OLE (n=579):
74% no x-ray progression at 3 yrs,
across all subgroups 💪
#EULAR2026 @RheumNow https://t.co/BftcHDKS4l
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
💉 Risankizumab durable in #PsA?
#POS0047 3 RCT n=964 KEEPsAKE
Yes! ACR50 ~37% & MDA ~34% @w244
no new safety signals 💪
#EULAR2026 @RheumNow https://t.co/911Fi9vxfP
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
🤔 Best endpoint for #PsA trials?
#POS0046: GRAPPA-OMERACT NMA (24 trials, n=12,000):
MDA wins! (OR 5.06) 📊
#EULAR2026 @RheumNow https://t.co/3KWaKcvF0a
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
🤔 GUS or IL-17i for #PsA?
#POS0045: RW study:
Both! ~76% persistence & similar effectiveness
1141 pts @12mo #PsABIOnd 🌍
#EULAR2026 @RheumNow https://t.co/PyuaH5B5V1
Jiha Lee JihaRheum
3 months 3 weeks ago
In #PsA, obesity isn't just a comorbidity, it's a disease modifier. Pooled SPIRIT trials (n=1284): 43% had obesity. BMI≥30 vs normal: joint counts ↑, function ↓, fatigue ↑, CVD 55% vs 18%, HTN 52% vs 11%, DM 19% vs 3%. @RheumNow #EULAR2026 POS0460
Janet Pope Janetbirdope
3 months 3 weeks ago
Does #Rx w #immunesuppression w
#antifibrotic
Help #SARD-ILD?
YES.
N=40 SARD-ILD, 1/2 w UIP pattern
Use of #IS w #antifibrotic pt group had better survival
Small N and ?channeling bias
But interesting results
TAke home : Use IS + antifibrotic
#EULAR2026 #POS0530
@RheumNow https://t.co/tfxVVw27jJ
Jiha Lee JihaRheum
3 months 3 weeks ago
Guselkumab in erosive #PsA: ACR20 68% vs 47% placebo, structural damage progression ↓ across subgroups regardless of sex, BMI, MTX use, or joint counts. Highest inflammation and erosion burden? Biggest benefit. IL-23i holds up where it matters most. @RheumNow #EULAR2026 POS0480
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an effective approach.
Jiha Lee JihaRheum
3 months 3 weeks ago
Not all "difficult-to-treat" #PsA definitions are equal. Real-world DEPAR cohort (n=885): 20% met GRAPPA complex-to-manage vs only 4% EULAR difficult-to-manage criteria. Definition choice determines who gets identified, and who gets left behind. @RheumNow #EULAR2026 POS0446
